secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2023-07-25T23:59:59+00:00
Accession:  0000950170-23-034234
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen appoints Thane Wettig as Interim CEO; Enrique Conterno resigns
-----------------------------------------------------------------------

- Thane Wettig, previously Chief Commercial Officer, named Interim CEO effective July 23, 2023.
- Enrique Conterno resigned as CEO and from the Board; will serve as Special Advisor through August 8, 2023.
- Conterno's resignation not due to any disagreement with the company.
- Wettig receives monthly $10,000 stipend on $545,000 base salary; bonus target rises to 75% of base as Interim CEO.
- Conterno entered consulting agreement at $35,000 per month through September 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017023034234/0000950170-23-034234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017023034234/fgen-20230721.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-034234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer